Skip to main content

Kodiak Sciences Inc. (KOD)

NASDAQ: KOD · IEX Real-Time Price · USD
111.97 2.31 (2.11%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap5.78B
Revenue (ttm)n/a
Net Income (ttm)-189.00M
Shares Out51.57M
EPS (ttm)-3.85
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume190,187
Open111.32
Previous Close109.66
Day's Range109.38 - 113.45
52-Week Range73.19 - 171.21
Beta1.37
AnalystsBuy
Price Target121.55 (+8.6%)
Est. Earnings DateNov 8, 2021

About KOD

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage pr...

IndustryBiotechnology
IPO DateOct 4, 2018
Employees76
Stock ExchangeNASDAQ
Ticker SymbolKOD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for KOD stock is "Buy." The 12-month stock price forecast is 121.55, which is an increase of 8.56% from the latest price.

Price Target
$121.55
(8.56% upside)
Analyst Consensus: Buy

News

3 Stocks Insiders Are Buying

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

Other symbols:ONSXT
1 month ago - Benzinga

Kodiak Sciences Inc. (KOD) Up 15.7% Since Last Earnings Report: Can It Continue?

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Kodiak Sciences Announces New Long-Term Performance Incentive Plan

PALO ALTO, Calif. , Sept. 1, 2021  /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to...

1 month ago - PRNewsWire

Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

PALO ALTO, Calif., Aug. 31, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

1 month ago - PRNewsWire

Kodiak Sciences (KOD) Q2 Earnings Lag, Eye Candidate in Focus

Kodiak Sciences (KOD) reports wider-than-expected loss for the second quarter of 2021. Pipeline development remains in focus for the company.

2 months ago - Zacks Investment Research

Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights

PALO ALTO, Calif., Aug. 9, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...

2 months ago - PRNewsWire

Is This Mid-Cap Biotech Stock a Buy Now?

This mid-cap growth stock could be a long-term winner.

Other symbols:ARKGREGN
2 months ago - The Motley Fool

Kodiak Sciences Has Declined $125M Funding From Baker Bros Citing Strong Balance Sheet

In December 2019, Kodiak Sciences Inc (NASDAQ: KOD) entered into a funding agreement with Baker Bros Advisors LP, wherein Baker Bros agreed to fund up to $225 million in exchange for the right to 4.5% r...

2 months ago - Benzinga

Why Is Kodiak Sciences Inc. (KOD) Down 4% Since Last Earnings Report?

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

Kodiak Sciences to Present at Upcoming Conferences

PALO ALTO, Calif., May 20, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...

4 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Kodiak Sciences Inc. - KOD

NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD).  Such investors are advised to cont...

4 months ago - PRNewsWire

Kodiak Sciences (KOD) Q1 Earnings Miss, KSI-301 in Focus

Kodiak Sciences (KOD) reports wider-than-expected loss for the first quarter of 2021. Pipeline development remains in focus for the company.

5 months ago - Zacks Investment Research

Why Kodiak Sciences Stock Is Tumbling Today

The company provided a first-quarter update with news that it's launching another late-stage clinical study of its lead candidate.

5 months ago - The Motley Fool

Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights

PALO ALTO, Calif., May 10, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...

5 months ago - PRNewsWire

What Makes Kodiak Sciences Inc. (KOD) a New Buy Stock

Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

5 months ago - Zacks Investment Research

Nielsen, Nordstrom, PayPal and More Friday Afternoon Analyst Calls

With the trading day nearing halfway over, the broad markets were somewhat mixed to close out the week.

7 months ago - 24/7 Wall Street

Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus

Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.

7 months ago - Zacks Investment Research

Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

PALO ALTO, Calif., March 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

7 months ago - PRNewsWire

Kodiak Sciences' KSI-301 Shows Durable Benefit In Retinal Disease Settings

Kodiak Sciences Inc (NASDAQ: KOD) announced new data from one-year durability, efficacy, and safety data from the ongoing Phase 1b study evaluating KSI-301, an intravitreal anti-VEGF antibody biopolymer...

7 months ago - Benzinga

Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patie...

PALO ALTO, Calif., Feb. 13, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

8 months ago - PRNewsWire

Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, a...

PALO ALTO, Calif., Feb. 2, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...

8 months ago - PRNewsWire

Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 5, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...

9 months ago - PRNewsWire

Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters...

PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

10 months ago - PRNewsWire

Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock

PALO ALTO, Calif., Nov. 17, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

10 months ago - PRNewsWire

Kodiak Sciences Announces Proposed Offering of Common Stock

PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...

10 months ago - PRNewsWire